Vitamin D deficiency is common in women with polycystic ovary syndrome (PCOS), with the 67-85% of women with PCOS having serum concentrations of 25-hydroxy vitamin D (25OHD) <20 ng/ml. Vitamin D deficiency may exacerbate symptoms of PCOS, with observational studies showing lower 25OHD levels were associated with insulin resistance, ovulatory and menstrual irregularities, lower pregnancy success, hirsutism, hyperandrogenism, obesity and elevated cardiovascular disease risk factors. There is some, but limited, evidence for beneficial effects of vitamin D supplementation on menstrual dysfunction and insulin resistance in women with PCOS. Vitamin D deficiency may play a role in exacerbating PCOS, and there may be a place for vitamin D supplementation in the management of this syndrome, but current evidence is limited and additional randomized controlled trials are required to confirm the potential benefits of vitamin D supplementation in this population.
vitamin D deficiency polycystic ovary syndrome, vitamin D supplementation PCOS insulin resistance, 25-hydroxy vitamin D levels PCOS symptoms, vitamin D PCOS menstrual irregularity ovulation, PCOS hyperandrogenism vitamin D association, vitamin D PCOS pregnancy success rates, PCOS cardiovascular risk factors vitamin D deficiency, vitamin D supplementation PCOS randomized controlled trial, Thomson Spedding Buckley vitamin D PCOS review, PCOS hirsutism obesity vitamin D serum concentration
PMID 22574874 22574874 DOI 10.1111/j.1365-2265.2012.04434.x 10.1111/j.1365-2265.2012.04434.x
Cite this article
Thomson RL, Spedding S, & Buckley JD (2012). Vitamin <scp>D</scp> in the aetiology and management of polycystic ovary syndrome. *Clinical Endocrinology*, *77*(3), 343-350. https://doi.org/10.1111/j.1365-2265.2012.04434.x
Thomson RL, Spedding S, Buckley JD. Vitamin <scp>D</scp> in the aetiology and management of polycystic ovary syndrome. Clinical Endocrinology. 2012;77(3):343-350. doi:10.1111/j.1365-2265.2012.04434.x
Thomson RL, et al. "Vitamin <scp>D</scp> in the aetiology and management of polycystic ovary syndrome." *Clinical Endocrinology*, vol. 77, no. 3, 2012, pp. 343-350.
Goshtasebi A et al., 2019
Open Access
Clinical Endocrinology
Objective: Many women use combined hormonal contraceptives (CHC) during adolescence during which they are accruing peak areal bone mineral density (BMD) that relates to lifetime fracture risk. To buil...
Bone Health > Contraception Impact > Adolescent Peak BMD AccrualContraception/Comparison > Combined Hormonal > Bone Health EffectsResearch Methodology > Meta-Analysis > Prospective Controlled Studies
OBJECTIVE: To our knowledge, data on comparison of myo-inositol and metformin on clinical, metabolic and genetic parameters in subjects with polycystic ovary syndrome (PCOS) are limited. This study wa...
Context: PTH is an essential regulator of mineral metabolism; PTH hypersecretion may result in hyperparathyroidism including normocalcaemic, primary and secondary hyperparathyroidism.
Objective: To e...
Bone Health > Mineral Metabolism > HyperparathyroidismBone Health > Bone Mineral Density > PTH and Skeletal MarkersResearch Methodology > Cross-Sectional Studies > Population-Based Cohorts
Objective: Thyroid hormones and progesterone both influence core temperature, metabolism and are crucial during pregnancy. Our objective was to discover whether progesterone therapy caused changes in ...